Purchase this article with an account.
Vanesa Freire, Juan A. Durán, Gonzalo Corcóstegui, Ainhoa Bilbao; Comparative viability profile of human corneal epithelial cells treated with Bevacizumab (Avastin®) and Aflibercept (Eylea®). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1193.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the viability of human corneal epithelial (HCE) cells treated with the new anti-VEGF agent Aflibercept, with those treated with Bevacizumab.
Experiments were performed using HCE cell line. HCE cells were seeded and cultured with our culture medium. Subsequently, to synchronize cultures, we substituted the initial culture medium for a medium with 1% bovine serum albumin (BSA) and incubation proceeded overnight. The HCE cells were treated with 0.5, 1.0, 1.5 o 2.0 mg/ml Bevacizumab or 0.5, 1.0, 1.5 o 2.0 mg/ml Aflibercept containing DMEN:F12 medium supplemented with 15% fetal bovine serum for 24 hours. Cell viability was measured by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay after incubating with the 3 different doses of Bevacizumab and Aflibercept.
The results show that only those cells treated with 2.0 mg/ml of Bevacizumab present statistically significant differences (p<0.01) with control. The viability of the cells treated with Aflibercept do not show statistically significant differences compared to control.
The cell viability assay shows that Aflibercept therapy appears to be at least as safe as treatment with Bevacizumab for HCE cells. Since Aflibercept has been proposed as a possible topical treatment of corneal neovascularization, more comprehensive safety studies are required.
This PDF is available to Subscribers Only